BioSpace News Archive

Blueprint Medicines Corporation announced that, effective August 1, 2022, the Compensation Committee of Blueprint Medicines’ Board of Directors granted non-qualified stock options to purchase an aggregate of 29,359 shares of its common stock and an aggregate of 14,675 restricted stock units to fourteen new employees under Blueprint Medicines’ 2020 Inducement Plan.

Evofem Biosciences, Inc., reported financial results for the three- and six-month periods ended June 30, 2022 and affirmed full-year 2022 guidance.

Ardelyx, Inc. (Nasdaq: ARDX), today reported business updates and financial results for the second quarter ended June 30, 2022.

Akebia Therapeutics®, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, announced initial findings from an investigator-sponsored study evaluating vadadustat, Akebia’s investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor, for the prevention and treatment of ARDS in clinical trial subjects with COVID-19 and hypoxemia.

Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today reported financial results and provided a business update for the quarter ending June 30, 2022.

Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus infection and other serious diseases, reported financial results for second quarter 2022 and provided a business update.

Cryoport, Inc. (NASDAQ: CYRX) (“Cryoport” or the “Company”), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced financial results for the three- and six-month periods ended June 30, 2022.

Biostage, Inc., a cell-therapy biotechnology company with successful first-in-human experience in treating esophageal cancer and FDA approval to commence a clinical trial of the Biostage Esophageal Implant, or BEI, for severe esophageal disease including cancer, announced its financial results and business updates for the second quarter ended June 30, 2022.

Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today reported financial results for the second quarter ended June 30, 2022 and provided business highlights.

Theravance Biopharma, Inc. (“Theravance Biopharma” or the “Company”) (NASDAQ: TBPH) today reported financial results for the second quarter of 2022.